Galmed Pharmaceuticals to Acquire Colospan, Creating GI-Focused Medtech Platform Targeting $6 Billion Colorectal Surgery Market
核心洞察
Galmed Pharmaceuticals entered a definitive agreement to acquire Colospan Ltd., a commercial-stage medical device company focused on colorectal surgery complications.
Colospan's CG-100 intraluminal bypass device (搜索) holds FDA Breakthrough Device Designation and CE mark, designed to reduce anastomotic leaks and eliminate the need for diverting stomas.
Galmed plans a $6 million investment to launch CG-100 commercially in Germany, Austria, and Switzerland during the second half of 2026.
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announced on June 8, 2026 that it has entered into a definitive agreement to acquire Colospan Ltd., a commercial-stage medical device company headquartered in Kfar Saba, Israel. The acquisition will reposition Galmed as a diversified, GI-focused medtech and biopharmaceutical platform, combining Galmed's public company infrastructure and GI clinical expertise with Colospan's proprietary device technology targeting one of colorectal surgery's most serious unmet needs.
The announcement sent Galmed shares down more than 16%, with the stock trading at $0.58 at the time of reporting.
CG-100: Addressing Anastomotic Leak (搜索) Complications
Colospan's flagship product, the CG-100 intraluminal bypass device (搜索), is a minimally invasive alternative designed to protect the anastomosis — the surgical connection created during colorectal resection — and reduce the need for a diverting stoma. Diverting stomas are temporary abdominal openings that redirect waste to an external bag while the anastomosis heals.
"Colorectal cancer (搜索) is the third most commonly diagnosed cancer in both men and women with approximately 1.9 million diagnosed cases worldwide annually," said Boaz Assaf, Founder and Chief Executive Officer of Colospan. "Colorectal resection is the most common medical treatment for colorectal cancer and is performed on a majority of patients worldwide to remove the tumor."
Anastomotic leaks, a failure of the surgical connection, occur in up to 21% of procedures, contributing to increased morbidity, mortality, longer hospital stays, and higher healthcare costs. To prevent clinical leaks, surgeons routinely create a diverting stoma. While clinically standard, living with a stoma significantly impairs quality of life and creates substantial clinical and economic burden for healthcare systems.
"Colospan was founded specifically to answer the clinical and economic burden associated with this problem, creating a stoma-free future for patients," Assaf added.
Regulatory Status and Commercial Plans
The CG-100 device has received FDA Breakthrough Device Designation and is CE marked under the EU's Medical Device Regulation (MDR), making it ready for commercial launch in Europe and Israel. In the United States, the device is currently under investigational use only under an FDA-approved Investigational Device Exemption (IDE), with Colospan conducting a pivotal clinical trial designed to support a future FDA application.
Galmed contemplates an investment of $6 million to launch the CG-100 device during the second half of 2026 in Europe, with an initial focus on Germany, Austria, and Switzerland.
Transaction Details
Under the terms of the definitive agreement, Colospan shareholders and SAFE holders will receive $2.5 million in cash and $2.0 million in Galmed ordinary shares at closing, subject to customary adjustments and escrow. The transaction has been unanimously approved by the boards of directors of both companies and is expected to close in the second quarter of 2026.
Allen Baharaff, Co-founder and Chief Executive Officer of Galmed Pharmaceuticals, described the acquisition as "a defining moment" for the company. "The acquisition of Colospan aligns perfectly with our long-term growth strategy. We are bringing more than 25 years of clinical execution capabilities together with our public company experience and resources to accelerate the CG-100 pivotal study to obtain FDA regulatory approval," Baharaff said. "We believe our shared vision will allow us to scale Colospan's technologies faster, and substantially accelerate our path to success."
Roth Capital Partners, LLC served as financial advisor to Galmed. Meitar Law Offices serves as legal counsel to Galmed, and Matry Meiri Wacht & Co. serves as legal counsel to Colospan.
Platform Strategy
Upon closing, Colospan will become a wholly owned subsidiary of Galmed. The combined entity will leverage Galmed's existing GI-focused pipeline, which includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule under evaluation across liver disease and oncological indications, including GI cancers. The acquisition is designed to create a diversified platform targeting both medtech and biopharmaceutical opportunities within the gastrointestinal space.